TherapeuticsMD (NYSE: TXMD) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $5.63 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.